Related Experiment Video
Updated: Jul 11, 2026
09:50
Induction of Intestinal Graft-versus-host Disease and Its Mini-endoscopic Assessment in Live Mice
Published on: February 11, 2019
Gastrointestinal complications in liver transplant recipients: MITOS study
J I Herrero1, S Benlloch, A Bernardos
1Clínica Universitaria, St Cruz de Tenerife, Spain. iherrero@unav.es
Transplantation Proceedings
|September 25, 2007
Summary
Gastrointestinal complications affect nearly half of liver transplant recipients, significantly impacting quality of life. Management often involves medication or adjusting immunosuppressive therapy.
Area of Science:
- Hepatology
- Transplant Surgery
- Gastroenterology
Background:
- Gastrointestinal (GI) complications are common in liver transplant recipients.
- Their prevalence and impact on quality of life remain understudied.
Purpose of the Study:
- To determine the prevalence of GI complications post-liver transplant.
- To assess the impact of these complications on patient quality of life.
- To analyze the management strategies for GI complications in this population.
Main Methods:
- An epidemiologic, cross-sectional, multicenter study.
- Recruited 417 liver transplant recipients across 14 centers.
- Utilized questionnaires for data collection.
Main Results:
- Nearly 50% of liver transplant recipients experienced GI complications post-transplant.
- Diarrhea was most prevalent; anorexia most impacted daily activities.
- Complications were more frequent in females, those with pre-transplant hiatal hernia, and readmitted patients.
- 70.9% received pharmacological treatment, often gastric protectors.
- Immunosuppressive therapy was modified in a significant portion of patients, with mycophenolate mofetil frequently altered.
Conclusions:
- GI complications affect approximately 50% of liver transplant recipients.
- These complications significantly impair quality of life.
- Risk factors include female gender, pre-existing GI issues, and post-transplant hospital admission.
- Management commonly involves pharmacological treatments and adjustments to immunosuppressive regimens.
